gummfd

Gazi Üniversitesi Mühendislik Mimarlık Fakültesi Dergisi

1300-1884 1304-4915

Gazi Üniversitesi

10.17341/gazimmfd.1740422

Biomedical Sciences and Technology Biomedical Therapy Control Theoryand Applications

Biyomedikal Bilimler ve Teknolojiler Biyomedikal Terapi Kontrol Teorisi ve Uygulamaları

Prostat kanserlerinde kapalı döngü aşı uygulaması: benzetim tabanlı bir yaklaşım

https://orcid.org/0000-0002-9217-0845

Doruk

Reşat Özgür

ATILIM ÜNİVERSİTESİ, MÜHENDİSLİK FAKÜLTESİ

03 31 2026

41 1 679 692 07 11 2025 01 30 2026

1986

Gazi Üniversitesi Mühendislik Mimarlık Fakültesi Dergisi

Bu çalışmanın amacı prostat kanseri immunoterapisinde uygulanabilecek kapalı döngü allojenik tam hücreli aşılama yöntemine ilişkin benzetim tabanlı bir yaklaşım geliştirmektedir. Bu noktada bir denetleyici tasarımı gerekli olup bu araştırmada Lyapunov'un ikinci kararlılık kuramından yararlanılmaktadır. Söz konusu amaca erişebilmek için, prostat kanseri olgusunun gelişimini tanımlayan yenilikçi bir matematiksel modele gereksinim duyulmaktadır. Bu çalışmada kullanılan modelde iki girdi yer almakta olup bunlar sırasıyla allojenik aşılama ve ikincil kemoterapi uygulama hızlarıdır. Yapılan tüm benzetimlerde değişik koşullar incelenmiştir. Bu şartlar alçak ve yüksek başlangış dozları, kontrollü ve serbest aşı uygulanması ve düşük düzeyli kemoterapinin eşlik edip etmemesi durumlarıdır. Yapılan benzetimlerde anlaşılmaktadır ki, eğer sadece düşük başlangıç dozlu bir aşı uygulanıyorsa tümör popülasyonu yavaşça artmaktadır. Kontrol uygulanmadığı durumlarda çok yüksek başlangıç dozu gerekmektedir. Kapalı döngüde ise düşük başlangış dozunda 65 gün içerisinde tam remisyon hali elde edilebilmektedir. Eğer son uygulama düşük dozlu bir kemoterapi ile desteklenirse anılan süre 11 güne kadar düşmektedir.

Prostat kanseri immünoterapi dendritik hücre aşılama Lyapunov kuramı kapalı döngü tedaviler

Yoktur. Tamamen kendi insiyatifimle yaptım.

1. Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F., Cancer statistics for the year 2020: An overview, International Journal of Cancer, 149 (4), 778-789, 2021.

2. Eastham J.A., Scardino P.T., Radical prostatectomy, Campbell’s urology, Springer, 1998.

3. Donovan J.L., Hamdy F.C., Lane J., Mason M., Metcalfe C., Walsh E., Blazeby J.M., Peters T.J., Holding P., Bonnington S., et al., Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer, N Engl J Med, 375 (15), 1425–1437, 2016.

4. Sharifi N., Gulley J.L., Dahut W.L., Androgen deprivation therapy for prostate cancer, Jama, 294 (2), 238–244, 2005.

5. Helsen C., Van den Broeck T., Voet A., Prekovic S., Van Poppel H., Joniau S., Claessens F., Androgen receptor antagonists for prostate cancer therapy, Endocrine-related cancer, 21 (4), 105–118, 2014.

6. De Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman Jr O.B., Saad F., et al., Abiraterone and increased survival in metastatic prostate cancer, New England Journal of Medicine, 364 (21), 1995–2005, 2011.

7. Marcelli M., Ittmann M., Mariani S., Sutherland R., Nigam R., Murthy L., Zhao Y., DiConcini D., Puxeddu E., Esen A., et al., Androgen receptor mutations in prostate cancer, Cancer research, 60 (4), 944–949, 2000.

8. Melief C.J., van Hall T., Arens R., Ossendorp F., van der Burg S.H., et al., Therapeutic cancer vaccines, The Journal of clinical investigation, 125 (9), 3401–3412, 2015.

9. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., et al., Sipuleucel-t immunotherapy for castration-resistant prostate cancer, New England Journal of Medicine, 363 (5), 411–422, 2010.

10. Trewartha D., Carter K., Advances in prostate cancer treatment, Nature reviews Drug discovery, 12 (11), 823-824, 2013.

11. Shenderov E., Antonarakis E.S., Reimagining vaccines for prostate cancer: back to the future, Clinical Cancer Research, 26 (19), 5056–5058, 2020.

12. Lundqvist A., Palmborg A., Bidla G., Whelan M., Pandha H., Pisa P., Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer t-cell responses, Medical Oncology, 21 (2), 155–165, 2004.

13. Muthumani K., Marnin L., Kudchodkar S.B., Perales-Puchalt A., Choi H., Agarwal S., Scott V.L., Reuschel E.L., Zaidi F.I., Duperret E.K., et al., Novel prostate cancer immunotherapy with a dna-encoded anti-prostate-specific membrane antigen monoclonal antibody, Cancer Immunology, Immunotherapy, 66 (12), 1577–1588, 2017.

14. Chau V., Madan R.A., Aragon-Ching J.B., Protein kinase inhibitors for the treatment of prostate cancer, Expert Opinion on Pharmacotherapy, 22 (14), 1889–1899, 2021.

15. Muhammad L.A., Saad F., The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target, Expert review of anticancer therapy, 15 (9), 1049–1061, 2015.

16. Loughlin K.R., Calcium channel blockers and prostate cancer, Urologic Oncology: Seminars and Original Investiga- tions, 32(5), 537–538, 2014.

17. Steinman R.M., Banchereau J., Taking dendritic cells into medicine, Nature, 449 (7161), 419–426, 2007. 18. Palucka K., Banchereau J., Cancer immunotherapy via dendritic cells, Nature Reviews Cancer, 12 (4), 265–277, 2012.

19. Rabinovich G.A., Gabrilovich D., Sotomayor E.M., Immunosuppressive strategies that are mediated by tumor cells, Annual Review of Immunology, 25 (1), 267–296, 2007.

20. Nishikawa H., Sakaguchi S., Regulatory T cells in tumor immunity, International Journal of Cancer, 127 (4), 759–767, 2010.

21. Rosenberg S.A., Restifo N.P., Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348 (6230), 62–68, 2015.

22. Raue A., Schilling M., Bachmann J., Matteson A., Schelke M., Kaschek D., Hug S., Kreutz C., Harms B.D., Theis F.J., et al., Lessons learned from quantitative dynamical modeling in systems biology, PloS ONE, 8 (9), 1-17, 2013.

23. Quaranta V., Weaver A.M., Cummings P.T., Anderson A.R., Mathematical modeling of cancer: the future of prog- nosis and treatment, Clinica Chimica Acta, 357 (2), 173–179, 2005.

24. Carotenuto A.R., Cutolo A., Palumbo S., Fraldi M., Lyapunov stability of competitive cells dynamics in tumor mechanobiology, Acta Mechanica Sinica, 37 (2), 244–263, 2021.

25. Borges F.S., Iarosz K.C., Ren H.P., Batista A.M., Baptista M.S., Viana R.L., Lopes S.R., Grebogi C., Model for tumour growth with treatment by continuous and pulsed chemotherapy, Biosystems, 116 (Feb), 43–48, 2014.

26. Quevedo J.A.Q., Asymptotic stability in a cancerimmunotherapy system, Revista Aristas, 8 (16), 132–138, 2021.

27. Doban A., Lazar M., An evolutionary–type model for tumor immunotherapy, IFAC-PapersOnLine, 48 (20), 575–580, 2015.

28. Zazoua A., Wang W., Analysis of mathematical model of prostate cancer with androgen deprivation therapy, Com- munications in Nonlinear Science and Numerical Simulation, 66 (Jan), 41–60, 2019.

29. Salim S.S., Mureithi E., Shaban N., Malinzi J., Mathematical modelling of the dynamics of prostate cancer with a curative vaccine, Scientific African, 11 (Mar), 1-13, 2021.

30. Yun Y.H., Lee B.K., Park K., Controlled drug delivery: historical perspective for the next generation, Journal of Controlled Release, 219 (Dec), 2–7, 2015.

31. Itik M., Salamci M.U., Banks S.P., Optimal control of drug therapy in cancer treatment, Nonlinear Analysis: Theory, Methods & Applications, 71 (12), 1473–1486, 2009.

32. Csercsik D., Sápi J., Kovács L., Model-based simulation and comparison of open-loop and closed-loop combined therapies for tumor treatment, 2018 IEEE Conference on Control Technology and Applications (CCTA), 1383–1388, 21-24 Ağustos, 2018.

33. Cacace F., Cusimano V., Germani A., Palumbo P., Papa F., Closed-loop control of tumor growth by means of anti-angiogenic administration, Mathematical Biosciences & Engineering, 15 (4), 827, 2018.

34. Angaroni F., Pennati M., Patruno L., Maspero D., Antoniotti M., Graudenzi A., A closed-loop optimization frame- work for personalized cancer therapy design, 2020 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), 1–9, 27-29 Ekim, 2020.

35. Li J., Liang J.Y., Laken S.J., Langer R., Traverso G., Clinical opportunities for continuous biosensing and closed-loop therapies, Trends in Chemistry, 2 (4), 319–340, 2020.

36. Joseph F.M., Hutapea P., Dicker A., Yu Y., Podder T., Closed loop control of a robot assisted smart flexible needle for percutaneous intervention, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), 3663–3666, 25-29 Ağustos, 2015.

37. Rossa C., Tavakoli M., Issues in closed-loop needle steering, Control Engineering Practice, 62 (May), 55–69, 2017.

38. [38] Podder T.K., Hutapea P., Darvish K., Dicker A., Yu Y., Smart needling system for fully conformal radiation dose delivery in treating prostate cancer, ASME 2010 Conference on Smart Materials, Adaptive Structures and Intelligent Systems, 893–896, 28 Eylül-01 Ekim, 2010.

39. Xu S., Kruecker J., Guion P., Glossop N., Neeman Z., Choyke P., Singh A.K., Wood B.J., Closed-loop control in fused mr-trus image-guided prostate biopsy, International Conference on Medical Image Computing and Computer- Assisted Intervention, 128–135, 29 Ekim – 02 Kasım, 2007.

40. Valle P.A., Coria L.N., Carballo K.D., Chemoimmunotherapy for the treatment of prostate cancer: Insights from mathematical modelling, Applied Mathematical Modelling, 90 (Feb), 682–702, 2021.

41. Cunningham W., An introduction to lyapunov’s second method, Transactions of the American Institute of Electrical Engineers, Part II: Applications and Industry, 80 (6), 325–332, 1962.

42. Korkmaz A.F., Ekinci F., Altaş Ş., Kumru E., Güzel M.S., Akata I., A deep learning and explainable ai-based approach for the classification of discomycetes species, Biology, 14 (6), 1-29, 2025.

43. Asan M.E., Taşkın H., Alemdar M., Capoglu R., Use of logistic regression in the diagnosis of thyroid cancer, Journal of the Faculty of Engineering and Architecture of Gazi University, 39 (3), 1509–1524, 2023.

44. Kalkan M., Guzel M.S., Ekinci F., Akcapinar Sezer E., Asuroglu T., Comparative analysis of deep learning methods on ct images for lung cancer specification, Cancers, 16 (19), 3321, 2024.

45. Üzülmez S., Çifçi M.A., Early diagnosis of lung cancer using deep learning and uncertainty measures, Journal of the Faculty of Engineering and Architecture of Gazi University, 39 (1), 385–400, 2023.

46. Ozsari S., Kumru E., Ekinci F., Akata I., Guzel M.S., Acici K., Ozcan E., Asuroglu T., Deep learning-based clas- sification of macrofungi: comparative analysis of advanced models for accurate fungi identification, Sensors, 24 (22), 1-22, 2024.

47. Ekinci F., Ugurlu G., Ozcan G.S., Acici K., Asuroglu T., Kumru E., Guzel M.S., Akata I., Classification of mycena and marasmius species using deep learning models: An ecological and taxonomic approach, Sensors, 25 (6), 1-21, 2025.

48. Akalın F., Yumuşak N., Classification of ALL, AML and MLL leukaemia types on microarray dataset using LSTM neural network approach, Journal of the Faculty of Engineering and Architecture of Gazi University, 38 (3), 1299–1306, 2023.

49. Kumru E., Ugurlu G., Sevindik M., Ekinci F., Güzel M.S., Acici K., Akata I., Hybrid deep learning framework for high-accuracy classification of morphologically similar puffball species using cnn and transformer architectures, Biology, 14 (7), 1-14, 2025.

50. Gürkan Ç., Budak A., Karataş H., Akın K., Segmentation of prostate zones on a novel MRI database using Mask R-CNN: An implementation on PACS system, Journal of the Faculty of Engineering and Architecture of Gazi University, 39 (3), 1401–1416, 2024.